Astroglia-Mediated Pathogenic Mechanisms in Fragile X Syndrome (FXS)
星形胶质细胞介导的脆性 X 综合征 (FXS) 致病机制
基本信息
- 批准号:10671282
- 负责人:
- 金额:$ 47.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-05-15 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:3&apos Untranslated RegionsAccelerationAffectAstrocytesAttenuatedBehavioralBindingBinding SitesBiochemicalBrainCellsDataDevelopmentDiseaseDown-RegulationElectrophysiology (science)FMR1Fragile X SyndromeFundingGene ExpressionGene SilencingGenesGeneticGenetic TranscriptionHumanHyperactivityHypersensitivityImageImpaired cognitionIn VitroInheritedInjectionsIntellectual functioning disabilityLengthMediatingMediatorMessenger RNAMicroRNAsMicrogliaMolecularMorphologyMusNeuronsNucleotidesOligodendrogliaOutcomePathogenesisPathogenicityPathway interactionsPhenotypePlayProteomeRNA-Binding ProteinsRegulationRoleSeizuresSensorySignal TransductionSpecific qualifier valueSynapsesTranslational RegulationTranslationsUntranslated RNAUp-RegulationVirusautisticbehavioral phenotypingconditional knockoutin vivomRNA Transcript DegradationmRNA Translationmemory acquisitionmessenger ribonucleoproteinmouse geneticsnerve stem cellneurotransmissionpostnatalpostnatal developmentrepetitive behaviorresponsesocialsoftware developmentsynaptic functionsynaptogenesistranscriptome
项目摘要
Abstract
Fragile X syndrome (FXS) is one of the most common inherited intellectual disabilities (ID) that is caused
by transcriptional silencing of the Fmr1 gene and loss of its encoded fragile X messenger ribonucleoprotein
(FMRP). FXS manifests with cognitive impairment, hyperactivity/seizure, sensory hypersensitivity, and several
autistic features such as repetitive behaviors and social withdraw. FMRP has been shown to be primarily a RNA-
binding protein that regulates translation of many mRNAs. In the mammalian CNS, astroglial cells play active
and diverse roles in modulating synaptogenesis and synaptic functions, especially during postnatal development.
How the loss of FMRP affects astroglial development and functions, especially underlying molecular
mechanisms, just begin to be understood. MicroRNAs (miRs) are a class of noncoding RNAs with a mature
length of 20-25 nucleotides that primarily bind to the 3’UTR of target mRNAs to significantly modulate gene
expression by either inhibiting mRNA translation or inducing mRNA degradation. Biochemical and genetic
evidence in neurons have implicated important roles of miR pathways in FMRP-mediated translational regulation.
Additionally, miRs play key roles in the specification of neural progenitor cells and oligodendrocyte and microglia
developmental maturation. Surprisingly, how miRs are involved in astroglial development especially postnatal
molecular and morphological maturation is essentially unknown. This represents a significant obstacle to better
understand astroglia-mediated pathogenic pathways in FXS.
Based on our preliminary results and progress we made during previous funding period in understanding
the role of astroglia in FXS pathogenesis, in this renewal, we propose the following aims: Aim 1: Determine the
roles of miR-128-3p in regulating postnatal astroglial development; Aim 2: Determine the pathogenic roles of
increased astroglial miR-128-3p in FXS. We have generated astroglial miR-128 conditional knock-out (Astro-
miR-128 CKO) and astroglial miR-128/Fmr1 double conditional knock-out (Astro-miR-128/Fmr1 DCKO) mice
and have generated a large amount of preliminary data to support our rationales and to demonstrate feasibility
for proposed aims. We will employ mouse genetics, primary astroglial cultures, electrophysiology, virus injections,
confocal and immunoEM imaging, and behavioral approaches to complete these aims. Outcomes from this
project will begin to define specific miRs that regulate postnatal astroglial molecular and morphological
maturation. In addition, the analysis of FXS-relevant synaptic and behavioral phenotypes on Astro-miR-128/Fmr1
DCKO mice will potentially provide a new astroglial target to modulate FXS disease development, thus will
significantly advance our understanding about astroglial mechanisms in FXS pathogenesis.
抽象的
脆弱的X综合征(FXS)是造成的最常见的继承智障(ID)之一
通过对FMR1基因的转录沉默和其编码脆弱的X信使色素蛋白的丧失
(FMRP)。 FXS表现出认知障碍,多动症/癫痫发作,感觉超敏反应以及几种
自闭症特征,例如重复行为和社交戒断。 FMRP已被证明是主要的RNA-
结合蛋白,调节许多mRNA的翻译。在哺乳动物中枢神经系统中,星形胶质细胞发挥活性
在调节突触发生和突触功能中的作用,尤其是在产后发育过程中。
FMRP的损失如何影响星形胶质的发育和功能,尤其是基础分子
机制,就开始被理解。 microRNA(mirs)是一类非编码RNA,成熟
初级结合靶mRNA的3'UTR以显着调节基因的20-25个核动肽长度
通过抑制mRNA翻译或诱导的mRNA降解来表达。生化和遗传
神经元中的证据已在FMRP介导的翻译调节中实施了MIR途径的重要作用。
另外,miR在神经祖细胞的规范中起关键作用,少突胶质细胞和小胶质细胞
发展成熟。令人惊讶的是,mir如何参与星形胶质发展,尤其是产后
分子和形态成熟基本上未知。这代表了更好的障碍
了解Astroglia介导的FXS中的致病途径。
基于我们在以前的资助期间的初步结果和进步
星形胶质细胞在FXS发病机理中的作用,在这种续签中,我们提出以下目的:目标1:确定
miR-128-3p在调节产后星形胶质成长中的作用;目标2:确定致病作用
FXS中的星形胶质细胞miR-128-3p增加。我们已经产生了星形胶质细胞mir-128条件淘汰赛(Astro-
miR-128 cko)和星形胶质细胞mir-128/fmr1双条件敲除(Astro-MIR-128/fmr1 DCKO)小鼠
并产生了大量的初步数据来支持我们的理由并证明可行性
对于拟议的目的。我们将采用小鼠遗传学,原发性星形型培养物,电生理学,病毒注射,
共焦和免疫成像以及完成这些目标的行为方法。结果
项目将开始定义调节产后星形胶质细胞和形态学的特定miRs
成熟。此外,在Astro-MIR-128/FMR1上的FXS相关突触和行为表型的分析
DCKO小鼠将有可能提供一个新的星形胶质细胞靶标,以调节FXS疾病的发展,因此将
显着提高了我们对FXS发病机理中星形胶质机制的理解。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yongjie Yang其他文献
Yongjie Yang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yongjie Yang', 18)}}的其他基金
Dysfunctional Astroglial Exosome to (motor) Neuron Axon Signaling in ALS
ALS 中星形胶质细胞外泌体与(运动)神经元轴突信号传导功能失调
- 批准号:
10556338 - 财政年份:2022
- 资助金额:
$ 47.73万 - 项目类别:
Dysfunctional astroglial exosome to (motor) neuron axon signaling in ALS
ALS 中星形胶质细胞外泌体与(运动)神经元轴突信号传导功能失调
- 批准号:
10364034 - 财政年份:2022
- 资助金额:
$ 47.73万 - 项目类别:
Exosomal miRNA in neuron to astroglial communication in the CNS
中枢神经系统神经元与星形胶质细胞通讯中的外泌体 miRNA
- 批准号:
10653994 - 财政年份:2020
- 资助金额:
$ 47.73万 - 项目类别:
Exosomal miRNA in neuron to astroglial communication in the CNS
中枢神经系统神经元与星形胶质细胞通讯中的外泌体 miRNA
- 批准号:
10435455 - 财政年份:2020
- 资助金额:
$ 47.73万 - 项目类别:
Exosomal miRNA in neuron to astroglial communication in the CNS
中枢神经系统神经元与星形胶质细胞通讯中的外泌体 miRNA
- 批准号:
10621422 - 财政年份:2020
- 资助金额:
$ 47.73万 - 项目类别:
Exosomal miRNA in neuron to astroglial communication in the CNS
中枢神经系统神经元与星形胶质细胞通讯中的外泌体 miRNA
- 批准号:
10200175 - 财政年份:2020
- 资助金额:
$ 47.73万 - 项目类别:
Exosomal miRNA signaling in Cocaine Addiction
可卡因成瘾中的外泌体 miRNA 信号传导
- 批准号:
9307767 - 财政年份:2016
- 资助金额:
$ 47.73万 - 项目类别:
Exosomes, MiRNAs and Astroglial Glutamate Transporter EAAT2/GLT1 Regulation
外泌体、miRNA 和星形胶质细胞谷氨酸转运蛋白 EAAT2/GLT1 调节
- 批准号:
8902283 - 财政年份:2014
- 资助金额:
$ 47.73万 - 项目类别:
Exosomes, MiRNAs and Astroglial Glutamate Transporter EAAT2/GLT1 Regulation
外泌体、miRNA 和星形胶质细胞谷氨酸转运蛋白 EAAT2/GLT1 调节
- 批准号:
8821167 - 财政年份:2014
- 资助金额:
$ 47.73万 - 项目类别:
相似海外基金
Understanding the full spectrum of epigenetic vulnerability in cancer through the delineation of DNA methylation function in gene 3' end
通过描绘基因 3 端 DNA 甲基化功能,全面了解癌症的表观遗传脆弱性
- 批准号:
10765365 - 财政年份:2023
- 资助金额:
$ 47.73万 - 项目类别:
The role of extracellular vesicle-associated MicroRNAs in HIV-associated atherosclerosis
细胞外囊泡相关 MicroRNA 在 HIV 相关动脉粥样硬化中的作用
- 批准号:
10619831 - 财政年份:2023
- 资助金额:
$ 47.73万 - 项目类别:
Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in Lymphoma
了解淋巴瘤对蛋白精氨酸甲基转移酶抑制剂的耐药机制
- 批准号:
10668754 - 财政年份:2023
- 资助金额:
$ 47.73万 - 项目类别:
New cell biology tools to study myelin development, dynamics, and disease
研究髓磷脂发育、动力学和疾病的新细胞生物学工具
- 批准号:
10649184 - 财政年份:2023
- 资助金额:
$ 47.73万 - 项目类别:
SELENOF is a Novel Tumor Suppressor and a New Target to Overcome Racial Disparity in Breast Cancer.
SELENOF 是一种新型肿瘤抑制剂,也是克服乳腺癌种族差异的新靶点。
- 批准号:
10735662 - 财政年份:2023
- 资助金额:
$ 47.73万 - 项目类别: